Israel Englander’s Context Therapeutics CNTX Stock Holding History

Israel Englander’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.6K	Sell	147,287 -1,277,087	-90%	-$2.59M	﹤0.01%	5542
2026 Q1	$3.73M	Sell	1,424,374 -1,176,842	-45%	-$2.75M	﹤0.01%	3263
2025 Q4	$3.82M	Buy	+2,601,216	New	+$3.04M	﹤0.01%	3300
2025 Q3	–	Sell	-17,067	Closed	-$11.2K	–	6077
2025 Q2	$11.2K	Sell	17,067 -31,604	-65%	-$22.7K	﹤0.01%	5715
2025 Q1	$29.8K	Sell	48,671 -130,047	-73%	-$113K	﹤0.01%	5591
2024 Q4	$188K	Buy	178,718 +34,835	+24%	+$60.3K	﹤0.01%	5330
2024 Q3	$282K	Buy	+143,883	New	+$319K	﹤0.01%	5229

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Israel Englander's CNTX Position: Q2 2026 in Review

Israel Englander reduced its Context Therapeutics (CNTX) stake by 90% in Q2 2026, selling an estimated $2.59M and leaving 147,287 shares worth $81.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5542.

Israel Englander first reported a position in CNTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.82M in Q4 2025. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Israel Englander held 147,287 shares of Context Therapeutics worth $81.6K as of Q2 2026.
Israel Englander sold 1,277,087 Context Therapeutics shares in Q2 2026, an estimated $2.59M.
Context Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5542 holding.
Israel Englander first reported a position in Context Therapeutics in Q3 2024 and has held it in 7 quarters since.
Israel Englander's Context Therapeutics position peaked at $3.82M in Q4 2025.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.